Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T16:38:44.221Z.
Calculation as of: 2026-10-06T16:38:44.221Z.
Quote observation: 2026-10-06T16:27:42.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: fd4e67db9f72c8f7e350226876d0b852307266b6ff0bede5899e1be1bde0c950
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Polaryx Therapeutics, Inc. Common Stock
Market Cap
$104.68M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$105.52M
Price/OCF Ratio
2.55
TTM Avg
3.01
3Y Avg
10.71
5Y Avg
28.96
Market Cap
$107.36M
Price/OCF Ratio
143.92
TTM Avg
45.05
3Y Avg
23.19
5Y Avg
15.20
Market Cap
$107.65M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$103.94M
Price/OCF Ratio
N/A
TTM Avg
17.45
3Y Avg
17.45
5Y Avg
17.45
Market Cap
$108.30M
Price/OCF Ratio
N/A
TTM Avg
8.98
3Y Avg
8.98
5Y Avg
8.98
Market Cap
$108.42M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc. Common Stock (PLYX) | $104.68M | N/A | N/A | N/A | N/A |
| Definitive Healthcare Corp. (DH)vs › | $105.52M | 2.55 | 3.01 | 10.71 | 28.96 |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.36M | 143.92 | 45.05 | 23.19 | 15.20 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $107.65M | N/A | N/A | N/A | N/A |
| Immunic, Inc. (IMUX)vs › | $108.02M | N/A | N/A | N/A | N/A |
| Anixa Biosciences, Inc. (ANIX)vs › | $103.94M | N/A | 17.45 | 17.45 | 17.45 |
| The Joint Corp. (JYNT)vs › | $102.85M | 19.09 | 39.64 | 28.03 | 30.91 |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $108.30M | N/A | 8.98 | 8.98 | 8.98 |
| Outlook Therapeutics, Inc. (OTLK)vs › | $108.42M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $103.06M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
